|[January 11, 2013]
Research and Markets: PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/w9jj3r/pharmapoint)
has announced the addition of GlobalData's new report "PharmaPoint:
Seasonal Influenza Vaccines United States Drug Forecast and Market
Analysis" to their offering.
Seasonal Influenza is a respiratory infection caused by influenza virus
that results in mild to severe symptoms, such as fever, cold and cough.
The market is heavily driven by the sales of prophylactic vaccine
treatments to prevent infection. Currently, trivalent intramuscular
vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's
Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of
However, with the entrance of vaccines with novel routes of
administration, such as AstraZeneca's intranasal FluMist and Sanofi's
Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the
adoption of such vaccines over the traditional intramuscular vaccines.
GlobalData also anticipates that manufacturers that launch quadrivalent
formulations will stea market share, patient share, and revenue from
the trivalent influenza vaccines currently available.
The US influenza vaccine market is valued at approximately $1.05 billion
in 2012. The projected drivers for market growth include increased
patient awareness on the importance of being vaccinated against
influenza, the introduction of vaccines with a quadrivalent formulation,
a growing elderly population, and introduction of vaccines with improved
efficacy in elderly patients.
Sanofi is the current market leader. It was among the first influenza
vaccines available in the US, and it has produced a diverse portfolio of
influenza vaccines under Sanofi's Fluzone brand. This brand includes
trivalent vaccines with novel routes of administration (Fluzone ID) and
vaccines with enhanced immunogenicity in elderly recipients (Fluzone
- Overview of seasonal influenza, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on the key drugs in the US including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting the US seasonal influenza market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely
to ensure a robust return
- Stay ahead of the competition by understanding the changing
competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth
analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the US.
For more information visit http://www.researchandmarkets.com/research/w9jj3r/pharmapoint
Source (News - Alert): GlobalData
[ InfoTech Spotlight's Homepage ]